0001209191-22-011437.txt : 20220218 0001209191-22-011437.hdr.sgml : 20220218 20220218181514 ACCESSION NUMBER: 0001209191-22-011437 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220216 FILED AS OF DATE: 20220218 DATE AS OF CHANGE: 20220218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: NORTHCOTT JOHN CENTRAL INDEX KEY: 0001615000 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24006 FILM NUMBER: 22654318 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH STREET 2: C/O NEKTAR THERAPEUTICS CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-02-16 0 0000906709 NEKTAR THERAPEUTICS NKTR 0001615000 NORTHCOTT JOHN C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94185 0 1 0 0 SVP & Chief Commercial Officer Common Stock 2022-02-16 4 S 0 4852 10.95 D 227802 D Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $10.77 to $11.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Mark A. Wilson, Attorney-in-Fact 2022-02-18